Europe Pharmacogenetic Testing in Psychiatry/Depression Market – Industry Trends and Forecast to 2028

  • Medical Devices
  • Published Report
  • Sep 2021
  • Europe
  • 350 Pages
  • No of Tables: 115
  • No of Figures: 47

Europe Pharmacogenetic Testing in Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-the-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research CentersCentres and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-to-Consumer Services and Mail-Order Pharmacies), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey and Rest of Europe) Industry Trends and Forecast to 2028.

Europe Pharmacogenetic Testing in Psychiatry/Depression Market

 

Market Analysis and Insights: Europe Pharmacogenetic Testing in Psychiatry/Depression Market  

The pharmacogenetic testing in psychiatry/depression market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.9% in the forecast period of 2021 to 2028 and is expected to reach USD 473.17 million by 2028. Growing prevalence of cancer disease, novel technology in pharmacogenetics testing for treatment of depression and pharmacogenomics testing are the major drivers which propelled the demand of the pharmacogenetic testing in psychiatry/depression market in the forecast period.

Pharmacogenetic test is a drug gene test which is used to determine the interaction between the drug and the genetic make-up of the individual. These tests aid the medical professionals to choose the best medicine for the person who is undertaking the drug because it is observed that different people react differently to drugs based on the expression of genes induced by the drugs.

With the rising prevalence of depression, the demand of pharmacogenetics testing is also increasing as it studies the effect of genetic variants with the aim of furnishing tailored treatment and the pharmacogenetic testing in psychiatry/depression market is expected to grow in coming years. The lack of basis to entirely depend on the tests is a major drawback in the pharmacogenetic testing in psychiatry/depression market. The patients would prefer to stick to traditional methods of testing and thus it will restrict the pharmacogenetic testing in psychiatry/depression market growth. The tests also help to establish a meaningful relationship between a drug and the genetic makeup of the individual. This helps in deciding the drugs to be administered to the patient to treat major depressive disorders and other psychiatric conditions acting as an opportunity for the pharmacogenetic testing in psychiatry/depression market growth. The stringent government regulation on new products and instruments approval will likely to challenge the pharmacogenetic testing in psychiatry/depression market growth.  

The pharmacogenetic testing in psychiatry/depression market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the pharmacogenetic testing in psychiatry/depression market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Pharmacogenetic Testing in Psychiatry/Depression MarketPharmacogenetic Testing in Psychiatry/Depression Market Scope and Market Size

The pharmacogenetic testing in psychiatry/depression market is categorized into seven notable segments which are based on the type, genes, drug type, sample, application, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the pharmacogenetic testing in psychiatry/depression market is segmented into whole genome sequencing and array-based tests. In 2021, whole genome sequencing segment is expected to dominate the market due to high technological adoption by key players in the market.
  • On the basis of genes, the pharmacogenetic testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and others. In 2021, CYP2C19 segment is expected to dominate the market due to increasing influence of genes on medications.
  • On the basis of drug type, the pharmacogenetic testing in psychiatry/depression market is segmented into prescription drugs, over-the-counter medications, recreational drugs and vitamins/nutraceuticals. In 2021, prescription drugs segment is expected to dominate the market due to increasing demand of personalized medicines.
  • On the basis of sample, the pharmacogenetic testing in psychiatry/depression market is segmented into saliva and blood. In 2021, saliva segment is expected to dominate the market because of advanced technologies present in the market.
  • On the basis of application, the pharmacogenetic testing in psychiatry/depression market is segmented into drug development and clinical practice. In 2021, drug development segment is expected to dominate the market because of rising demand of precision diagnosis.
  • On the basis of end user, the pharmacogenetic testing in psychiatry/depression market is segmented into pharmaceutical & biotechnology companies, research centers and academic institutes, healthcare providers and others. In 2021, pharmaceutical & biotechnology companies segment is expected to dominate the market because of large number of players present in the market.
  • On the basis of distribution channel, the pharmacogenetic testing in psychiatry/depression market is segmented into hospital pharmacies, retail pharmacies, direct-to-consumer services and mail-order pharmacies. In 2021, hospital pharmacies segment is expected to dominate the market because of increasing demand of customized and precision diagnosis.

Europe Pharmacogenetic Testing in Psychiatry/Depression Market Country Level Analysis

The pharmacogenetics testing in psychiatry/depression market is categorized into seven notable segments which are based on the type, genes, drug type, sample, application, end user and distribution channel.

The countries covered in the Europe pharmacogenetic testing in psychiatry/depression market report are the Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey and rest of Europe.

The U.K. is expected to grow with the most promising growth rate in the Europe pharmacogenetic testing in psychiatry/depression market in the forecast period of 2021 to 2028 with rising usage of pharmacogenetic testing in psychiatry/depression in breast cancer, lung cancer, prostate cancer, colorectal cancer, lymphoma, liver cancer, thyroid cancer, brain cancer, cervical cancer, spine cancer and others in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

New Product Launches by Manufacturers is Creating New Opportunities for Players in the Pharmacogenetics Testing in Psychiatry/Depression Market 

The pharmacogenetic testing in psychiatry/depression market also provides you with detailed market analysis for every country growth in aesthetic industry with pharmacogenetic testing in psychiatry/depression sales, impact of advancement in the pharmacogenetic testing in psychiatry/depression and changes in regulatory scenarios with their support for the pharmacogenetic testing in psychiatry/depression market. The data is available for historic period 2011 to 2019.    

Competitive Landscape and Pharmacogenetic Testing in Psychiatry/Depression Market Share Analysis

The pharmacogenetic testing in psychiatry/depression market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Europe pharmacogenetic testing in psychiatry/depression market.  

The major players covered in the Europe pharmacogenetic testing in psychiatry/depression market report are Myriad Genetics, Inc., AltheaDx, STADA Arzneimittel AG, Sonic Healthcare, Thermo Fisher Scientific Inc., Coriell Life Sciences, AB-Biotics, S.A., F. Hoffmann-La Roche Ltd, Luminex Corporation, Illumina, Inc., PerkinElmer Inc., myDNA Life Australia Pty Ltd., R-Biopharm AG among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the pharmacogenetic testing in psychiatry/depression market.

For instance,  

  • In July 2020, Myriad Genetics, Inc. announced the launch of a home collection kit for patients for the GeneSight Psychotropic Test. The test will help the doctors understand the impact of anti-depressants and other drugs related to the same on the genetic makeup of the patient. This will help them administer drugs that will be suitable for their patients improving the outcomes. This will help in the growth of the market in fore coming years.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the pharmacogenetic testing in psychiatry/depression market which also provides the benefit for organisation to improve their offering for pharmacogenetic testing in psychiatry/depression.

Customization Available: Europe Pharmacogenetic Testing in Psychiatry/Depression Market  

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD MILLION)

TABLE 2 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 EUROPE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD MILLION)

TABLE 5 EUROPE CYP2C19 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 EUROPE CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 EUROPE CYP2D6 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 EUROPE HLA-B IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 EUROPE HTR2A/C IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 EUROPE HLA-A IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 EUROPE CYP3A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 EUROPE SLC6A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 EUROPE MTHFR IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 EUROPE COMT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 EUROPE OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD MILLION)

TABLE 17 EUROPE PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 EUROPE OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 EUROPE RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 EUROPE VITAMINS/NUTRACEUTICALS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD MILLION)

TABLE 22 EUROPE SALIVA IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 EUROPE BLOOD IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD MILLION)

TABLE 25 EUROPE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 EUROPE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD MILLION)

TABLE 28 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 EUROPE HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 EUROPE RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 EUROPE OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD MILLION)

TABLE 33 EUROPE RETAIL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 EUROPE HOSPITAL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 EUROPE MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION))

TABLE 36 EUROPE DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

TABLE 38 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 39 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 40 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 41 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 42 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 43 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 44 EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 45 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 46 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 47 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 48 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 49 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 50 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 51 U.K. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 52 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 53 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 54 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 55 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 56 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 57 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 58 GERMANY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 59 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 60 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 61 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 62 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 63 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 64 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 65 FRANCE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 66 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 67 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 68 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 69 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 70 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 71 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 72 ITALY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 73 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 74 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 75 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 76 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 77 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 78 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 79 SPAIN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 80 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 81 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 82 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 83 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 84 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 85 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 86 NETHERLANDS PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 87 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 88 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 89 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 90 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 91 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 92 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 93 BELGIUM PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 94 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 95 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 96 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 97 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 98 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 99 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 100 RUSSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 101 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 102 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 103 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 104 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 105 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 106 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 107 SWITZERLAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 108 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 109 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)

TABLE 110 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 111 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)

TABLE 112 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 113 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 114 TURKEY PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 115 REST OF EUROPE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions